OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has earned an average rating of “Hold” from the ten research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $6.33.
A number of research firms have recently commented on OMED. Cantor Fitzgerald reissued a “hold” rating and set a $6.00 target price on shares of OncoMed Pharmaceuticals in a research note on Tuesday, April 25th. JMP Securities cut shares of OncoMed Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, April 17th. SunTrust Banks, Inc. cut shares of OncoMed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, April 17th. Piper Jaffray Companies set a $5.00 target price on shares of OncoMed Pharmaceuticals and gave the stock a “hold” rating in a research note on Monday, July 10th. Finally, ValuEngine cut shares of OncoMed Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
OncoMed Pharmaceuticals (NASDAQ OMED) opened at 3.88 on Friday. The company’s market cap is $146.00 million. The firm’s 50 day moving average is $3.53 and its 200 day moving average is $5.68. OncoMed Pharmaceuticals has a 12-month low of $2.91 and a 12-month high of $12.58.
OncoMed Pharmaceuticals (NASDAQ:OMED) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. The company had revenue of $6.20 million for the quarter, compared to analysts’ expectations of $6.08 million. The firm’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.91) EPS. Equities research analysts anticipate that OncoMed Pharmaceuticals will post ($1.85) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Receives Consensus Recommendation of “Hold” from Analysts” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.com-unik.info/2017/08/12/oncomed-pharmaceuticals-inc-nasdaqomed-receives-consensus-recommendation-of-hold-from-analysts.html.
In other OncoMed Pharmaceuticals news, Director Jack W. Lasersohn acquired 23,507 shares of the company’s stock in a transaction that occurred on Tuesday, May 16th. The stock was bought at an average price of $3.49 per share, with a total value of $82,039.43. Following the purchase, the director now owns 131,095 shares in the company, valued at $457,521.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jonathan D. Root sold 7,487 shares of the company’s stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $3.70, for a total transaction of $27,701.90. Following the sale, the director now directly owns 121,020 shares of the company’s stock, valued at approximately $447,774. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 88,121 shares of company stock valued at $304,289. 32.80% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in OMED. SG Americas Securities LLC boosted its stake in shares of OncoMed Pharmaceuticals by 312.7% in the first quarter. SG Americas Securities LLC now owns 58,626 shares of the biopharmaceutical company’s stock valued at $540,000 after buying an additional 44,419 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of OncoMed Pharmaceuticals during the first quarter valued at about $372,000. Ameriprise Financial Inc. acquired a new stake in shares of OncoMed Pharmaceuticals during the first quarter valued at about $6,266,000. Swiss National Bank boosted its stake in shares of OncoMed Pharmaceuticals by 22.1% in the first quarter. Swiss National Bank now owns 33,200 shares of the biopharmaceutical company’s stock valued at $306,000 after buying an additional 6,000 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of OncoMed Pharmaceuticals by 5.1% in the first quarter. Bank of New York Mellon Corp now owns 109,273 shares of the biopharmaceutical company’s stock valued at $1,007,000 after buying an additional 5,305 shares in the last quarter. 44.20% of the stock is owned by institutional investors.
OncoMed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
What are top analysts saying about OncoMed Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OncoMed Pharmaceuticals Inc. and related companies.